| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
You are here > Biopharmaceutical Glossary Homepage > Drug discovery & development > Therapeutic areas: Cardiovascular, CNS, Immunology, Infectious, Inflammation
Therapeutic indications: SCOPE
NOTE: cardiovascular:
Antibacterial Discovery and Development
September 26-27, 2018
Boston, MA
Program |
New discovery platforms, novel screens and approaches are vital for the
discovery of new antibacterials and for ceasing the dangerous trends of
multidrug microbial resistance. Gram-negative bacteria are one of the main
challenges for the healthcare system and public health in general.
Gram-negative bacteria have specific scientific problems such as low
permeability of the outer membrane that must be overcome, complicated and
multiple resistance mechanisms, etc. autistic disorder: A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V) MeSH Medical Subject Headings Year introduced: 1981(1966)
Autoimmune and Inflammation Drug Targets
September 27-28, 2018 Boston, MA
Program
biodefense:
Biodefense World Summit 2019 June, San Diego CA
https://www.biodefenseworldsummit.com/
pathogen detection, point-of-care, biosurveillance, sample prep
technologies, and bio recovery. blood brain barrier: See Drug Delivery blood brain barrier blood substitutes: Human blood, plasma and tissue contain many proteins, the extraction and purification of which are of great medical and economic importance. Transmission of infectious diseases via blood transfusion, tissue implantation and the use of processed blood plasma and components have placed a high priority on the development of new strategies for safeguarding the health of millions of patients who receive blood and tissue-derived products every year. The screening of blood for the detection of infectious agents is continuing to advance but is complicated by the presence of new and emerging pathogens. In addition, cost- effectiveness and the threat of emerging and/or crossover infective agents must also be considered. BSE: Bovine spongiform encephalopathy (or mad cow disease). See also TSE CJD Creutzfeldt- Jakob disease: Related terms: BSE, blood & blood substitutes, TSE Transmissible Spongiform Encephalopathy Narrower term: vCJD Variant Creutzfeldt-Jakob disease cardiac disease: Guidance for industry, Somatic cell therapy for, FDA 2010 Guidance for Industry - FDA cardiovascular models: Theoretical representations that simulate the behavior or activity of the cardiovascular system, processes, or phenomena; includes the use of mathematical equations, computers and other electronic equipment. MeSH 1980 CNS Targets June 18=19 2019, Boston MA https://www.pharmaweek.com/Translational-Strategies-CNS/ A greater understanding of CNS related disease biology and the emergence of new, improved targets and technologies is bringing renewed interest, excitement and investment into this transformative area of medicine. Cambridge Healthtech Institute’s CNS Targets and Translational Strategies conference focuses on the key issues of CNS drug development – including CNS target discovery and validation, biomarkers, bridging the preclinical/ clinical translation gap, evaluating the strengths and weaknesses of current preclinical models, challenging “gold-standards”, understanding mechanism of action, dose selection, neuroimaging, neuroinflammation, neuroimmunology, and more CNS and Neurodegenerative Targets September 26-27, 2018 Boston, MA Program | The identification of therapeutic targets based on novel mechanistic approaches is urgently needed for CNS and neurodegenerative diseases, particularly for conditions such as Alzheimer’s which represent extensive unmet medical need and blockbuster potential for the right therapy. Driven by an improving understanding of CNS disease biology and the emergence of new mechanisms and targets, Cambridge Healthtech Institute’s CNS and Neurodegenerative Targets conference profiles the latest tools, targets and platforms driving today’s CNS drug discovery strategies, with critical updates and findings in key areas such as new targets for misfolded proteins, tau, GCPRs, kinase inhibitors, genetics, gene therapy, and neuroinflammation. cosmetic psychopharmacology: https://en.wikipedia.org/wiki/Cosmetic_pharmacology Peter Kramer, Listening to Prozac, Wikipedia http://en.wikipedia.org/wiki/Peter_D._Kramer emerging infectious diseases: See Scope Note Emerging Infectious Diseases, CDC, US http://www.cdc.gov/ncidod/eid/about.htm published monthly Gram Negative Pathogens Targeting September 27-28, 2018 Boston, MA Program | Multidrug-resistant Gram-negative bacteria are one of the main challenges for the healthcare system and public health in general. Gram-negative bacteria have specific scientific problems, such as low permeability of the outer membrane that must be overcome, complicated and multiple resistance mechanisms, etc. immunogenetics:
Concerns
that branch of genetics that deals with the genes which regulate the immune
response. Immunogenetics arose in the 1960s born out of interest in the human
leucocyte antigens (HLAs) and their role in transplant acceptance and rejection.
The idea that the immune response is under genetic control however predates the
clinical need to study HLA, and its origins can be traced back to earlier in the
20th century, with truly great scientists (Landsteiner, Gorer, Snell, Medawar,
and Dausset, to name but a few). (Current and up to date. Immunogenetics was
never a science that was restricted to studies of HLA. The ABO blood groups,
immunoglobulin, and complement gene polymorphisms have long been included in the
list. More recently, however, we have come to understand the extent of
polymorphism in the human genome, and have realised almost any gene that encodes
an immune active product can act as an “immune response gene.”
…
Most
studies to date have been concerned with the human MHC, but an increasing number
of investigators are now focussing on other immunogenes that affect both innate
and acquired immunity to self and foreign antigens.
P
T Donaldson, Genetics of liver disease:
immunogenetics and disease pathogenesis, Gut.
2004
April; 53(4):
599–608 doi:
10.1136/gut.2003.031732
immunogenomics
The
immunogenomics data analysis working group (IDAWG) is an international
collaboration
of histocompatibility
and immunogenetics investigators who
share the goal of facilitating the sharing of immunogenomic data (HLA, KIR,
etc.) and fostering the consistent analysis and interpretation of those data by
the immunogenomics community and the larger genomics communities.
The
working group was formed in advance of the 16th
International HLA and Immunogenetics Workshop (IHIW) and Conference with
the intent to present its recommendations on topics of data-management and
data-analysis at the 16th IHIW and Conference in 2012. IDAWG projects continue
in anticipation of the 17th IHIW meeting to be held in 2017.
http://www.immunogenomics.org/ immunological models: Theoretical representations that simulate the behavior or activity of immune system, processes, or phenomena. They include the use of mathematical equations, computers, and other electrical equipment. MeSH 1995 Immunomodulatory Therapeutic Antibodies Autoimmune, Infectious and Neurological Diseases August 13-14, 2020 Boston, MA With the incidence of age-related neurodegenerative diseases expected to increase significantly over the next decade, the challenge of effectively treating autoimmune diseases, and the continuing issue of infectious diseases remaining a leading cause of mortality worldwide, new treatment strategies are urgently needed. In many cases, the best hope for better health outcomes lies in exploiting the immune system to achieve therapeutic effect. https://www.immuno-oncologysummit.com/Immunomodulatory-Antibodies-Cancer/
immunotherapy: Biologics
immunotherapy cancer infectious disease models: Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models will be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid public officials in their decision-making processes. National Institute of General Medical Sciences, NIH https://www.nigms.nih.gov/research/specificareas/MIDAS/pages/default.aspx infectious disease ontology: http://infectiousdiseaseontology.org/page/Main_Page
Inflammation Inhibitors
Medicinal Chemistry
for Oral-Based Autoimmune and Inflammation Related Therapeutics lipoproteomics: Karlsson H, Leanderson P, Tagesson C, Lindahl M, Lipoproteomics I: mapping of proteins in low-density lipoprotein using two- dimensional gel electrophoresis and mass spectrometry Proteomics. 5(2): 551-65, 2005 Feb Related term: cardiogenomics microbial proteomics: Bacterial genomes encode all possible virulence determinants, vaccine candidates, and potential drug targets. Further, a completed genomic sequence establishes a basis for high throughput analysis of the proteins expressed (i.e., the proteome). Respiratory pathogens have been among the first to have their genomes entirely sequenced.
Molecular Diagnostics for Infectious Disease
March 2-4, 2020 San Francisco, CA
| Advancing
Molecular Diagnostics to Improve Detection and Patient Outcome
With NGS assays moving into clinical use and
new technologies being developed for a host of infectious diseases, it is
more important than ever to keep on top of the latest advances in the
field. Cambridge Healthtech Institute’s 4th Annual Molecular Diagnostics
for Infectious Disease symposium will discuss in detail the process of
moving sequencing into clinical use, with an examination of reference vs.
clinical labs, metagenomics vs. panel-based tests, investments in
bioinformatics, and physician education. We will also examine rapid
susceptibility testing in the light of the new breakpoints, how they are
used, and the role genotypic vs. phenotypic testing. Special attention
will also be paid to new technologies for host response and clinical
applications of microbiome analysis. We will also have a discussion
centered around the regulatory landscape for NGS diagnostics and what to
expect as we will look into the future of molecular diagnostics for
infectious disease.
NASH and Fibrosis
September 17-18, 2019 Boston, MA
|
Drug development for the fatty liver
Non-alcoholic Steatohepatitis (NASH) is a disease of the liver that starts
with an accumulation of fat and proceeds to inflammation and scarring of
the liver. The scarring begins as fibrosis, but can worsen to cirrhosis
and eventual liver failure. The global incidence of NASH is rapidly rising
and no medical treatments exist. Advances in the scientific understanding
of the fibrotic disease process in other organs are also rapidly
occurring.
NeuroCommons:
The NeuroCommons project seeks to make all scientific research materials -
research articles, knowledge bases, research data, physical materials - as
available and as usable as they can be. We do this by fostering practices
that render information in a form that promotes uniform access by
computational agents - sometimes called "interoperability".
http://neurocommons.org/page/Main_Page neurological models: Theoretical representations that simulate the behavior or activity of the neurological system, processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. MeSH 1977 neuropharmaceuticals: Drugs targeting the central nervous systems. The blood brain barrier poses a formidable drug delivery challenge. Related terms: cogniceuticals, neuroceuticals, neuroinformatics
neuroproteomics:
now proteomics gives way to neuroproteomics as we begin to
unravel the complex mysteries of neurological diseases that less than a
generation ago seemed opaque to our inquiries, if not altogether intractable.
... Bolstered by each new discovery, researchers employing multiple methods
of inquiry gain a deeper understanding of the key biological problems related to
brain function, brain structure, and the complexity of the nervous system. …
Approaches discussed in the book include mass spectrometry, electrophoresis,
chromatography, surface plasmon resonance, protein arrays, immunoblotting,
computational proteomics, and molecular imaging. Neuroproteomics Frontiers
in Neuroscience Edited by Oscar Alzate, CRC Press 2010 http://www.ncbi.nlm.nih. Protein profiling related to CNS cells, tissues and neurodegenerative and neuropsychiatric conditions. Neurotech Investing & Partnering Conference 2020 May 5-6 Boston MA keynotes, investor panels, cutting-edge company presentations and a comprehensive selection of neurotech topics. https://www.neurotechpartnering.com/ phyloproteomics:
Identification of unknown bacterial isolates based on similarities within protein
biomarker databases. [Gregory C. Conway et. al. "Phyloproteomics: Species Identification of
Enterobacteriaceae Using Matrix- Assisted Laser Desorption/ Ionization
Time- of- Flight Mass Spectrometry" J. Mol. Micro. Biotechnol. 3: 103-112,
2001 PrPC proteins: Normal cellular isoform of prion proteins (PRIONS) encoded by a chromosomal gene and found in normal and scrapie- infected brain tissue, and other normal tissue. PrPC are protease- sensitive proteins whose function is unknown. Post- translational modification of PrPC into PrPSC leads to infectivity. MeSH, 1995 PrPSc proteins: Abnormal isoform of prion proteins (PRIONS) resulting from a posttranslational modification of the cellular prion protein (PRPC PROTEINS). PrPSc are disease-specific proteins seen in certain human and animal neurodegenerative diseases (PRION DISEASES). MeSH, 1995 psychogenomics: Used here to describe the process of applying the powerful tools of genomics and proteomics to achieve a better understanding of the biological substrates of normal behavior and of diseases of the brain that manifest themselves as behavioral abnormalities. Applying psychogenomics to the study of drug addiction will lead to the identification of genes and their protein products that control the reward pathways of the brain and their adaptations to drugs of abuse, as well as variations in these genes that confer genetic risk for addiction and related disorders. EJ Nestler, Psychogenomics: opportunities for understanding addiction, J Neurosci. 21(21): 8324- 8327, Nov 1, 2001 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11606619&query_hl=38 psychoneuroimmunology: The Psychoneuroimmunology Research Society is an international organization for researchers in a number of scientific and medical disciplines including psychology, neurosciences, immunology, pharmacology, psychiatry, behavioral medicine, infectious diseases, endocrinology and rheumatology, who are interested in interactions between the nervous system and the immune system, and the relationship between behavior and health. https://www.pnirs.org/index.cfm Related terms: neuroimmune network, neuroimmunoendocrinology, neuroimmunomodulation
systems
immunotechnology
Our group’s overall research interests are in the
emerging field of experimental systems immunology, which is at the intersection
of molecular biotechnology and immunology. Research in systems immunology is
focused on gaining a more comprehensive and quantitative understanding of the
immune system. This includes the use of high-throughput molecular technologies
such as next generation DNA sequencing, quantitative proteomics, bioinformatics,
and protein engineering. These approaches enable us to develop an immunological
toolbox capable of addressing a wide spectrum of human diseases. For example,
immunoglobulin repertoires (antibodies and TCRs) can be quantitatively profiled
by high-throughput DNA sequencing and quantitative proteomics. These tools are
providing an unprecedented level of information depth on the distribution of
adaptive immune cell functionalities and diversity, which develop upon
activation following vaccination, pathogenic infection, or disease.
Therapeutic indications resources
Insight
Pharma Reports therapeutic indications
https://www.insightpharmareports.com/therapeutic-indications
|
Contact
| Privacy Statement |
Alphabetical
Glossary List | Tips & glossary
FAQs | Site Map
